上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。
Fusarochromanone (Synonyms: FC-101)
Fusarochromanone (FC-101) 是一种真菌代谢物，具有有效的抗血管生成和抗癌活性。Fusarochromanone 激活的 JNK 通路归因于活性氧 (ROS) 的诱导。
Fusarochromanone Chemical Structure
CAS No. : 802915-53-3
| 规格 |
|
是否有货 |
|
| 100 mg |
|
询价 |
|
| 250 mg |
|
询价 |
|
| 500 mg |
|
询价 |
|
* Please select Quantity before adding items.
| 生物活性 |
Fusarochromanone (FC-101) is a fungal metabolite with potent anti-angiogenic and anti-cancer activity[1]. Fusarochromanone-activated JNK pathway is attributed to induction of reactive oxygen species (ROS)[2].
|
体外研究
(In Vitro) |
Fusarochromanone (FC101; 10 μM; 24 hours) induces apoptosis and an increase in proportion of cells in the sub-G1 phase in both HaCat and P9-WT cell lines[1].
Fusarochromanone (FC101; 0-1 μM; 24 h) induces the cleavage of both caspase-3 and PARP, a well-known substrate for activated caspases. FC101 does not affect the expression of the anti-apoptotic proteins, Bcl-2, Bcl-XL, Mcl-1, or the pro-apoptotic proteins BAD, BAK, BAX[1].
Fusarochromanone (FC101) exhibits very potent in-vitro growth inhibitory effects (IC50 ranging from 10 nM-2.5 μM) against HaCat (pre-malignant skin), P9-WT (malignant skin), MCF-7 (low malignant breast), MDA-231 (malignant breast), SV-HUC (premalignant bladder), UM-UC14 (malignant bladder), and PC3 (malignant prostate) in a time-course and dose-dependent manner, with the UM-UC14 cells being the most sensitive.
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Cycle Analysis[1]
| Cell Line: |
HaCat and P9-WT cell lines |
| Concentration: |
10 μM |
| Incubation Time: |
24 hours |
| Result: |
Showed cells in the G2 and M phases of the cell cycle for both cell lines. |
Western Blot Analysis[1]
| Cell Line: |
MDA-MB-231 cells |
| Concentration: |
0.05 μM, 0.1 μM, 0.2 μM, 0.5 μM, 1 μM |
| Incubation Time: |
24 hours |
| Result: |
Induced the cleavage of both caspase-3 and PARP. |
|
体内研究
(In Vivo) |
Fusarochromanone (8 mg/kg; IP; 5 days per week; for 3.5 weeks) Is well tolerated, non-toxic, and achieved a 30% reduction in tumor size at a dose of 8 mg/kg/day[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: |
SCID Beige mice (CB17/Icr.Cg-PrkdcscidLystbg/Crl) injected with SRB12-p9 cells[1] |
| Dosage: |
8 mg/kg |
| Administration: |
IP; 5 days per week; for 3.5 weeks |
| Result: |
Achieved a 30% reduction in tumor size at a dose of 8 mg/kg/day. |
|
| 分子量 |
|
| Formula |
|
| CAS 号 |
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
| 参考文献 |
-
[1]. Elahe Mahdavian, et al.Biological activities of fusarochromanone: a potent anti-cancer agent. BMC Res Notes. 2014 Sep 3;7:601.
[2]. Ying Gu, et al.Fusarochromanone-induced reactive oxygen species results in activation of JNK cascade and cell death by inhibiting protein phosphatases 2A and 5. Oncotarget. 2015 Dec 8;6(39):42322-33.
|
所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务
